Upper Gastrointestinal, Pancreatic & Liver
The following list provides a brief description of upper gastrointestinal, pancreatic and liver cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
Abraxis CA046 Study
|
Registered Title |
A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas. |
|
Purpose |
N/A |
|
Lay Summary |
N/A |
|
WA Trial Sites |
SCGH Medical Oncology |
|
Links |
Acknowledgements: US National Library of Medicine
Imclone Gastric Study
|
Registered Title |
A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy. |
|
Purpose |
The purpose of this study is to gather information about the use of an investigational drug called IMC-1121B (Ramucirumab) in adenocarcinomas of the gastroesophageal junction. |
|
Lay Summary |
N/A |
|
WA Trial Sites |
RPH Medical Oncology |
|
Links |
Acknowledgements: US National Library of Medicine
LAP07 Study
|
Registered Title |
Randomized Multicenter Phase III Study in Patients With Locally Advanced Adenocarcinoma of the Pancreas: Gemcitabine With or Without Chemoradiotherapy and With or Without Erlotinib. Intergroup Study. |
|
Purpose |
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which regimen of chemotherapy with or without erlotinib and/or radiation therapy is most effective in treating pancreatic cancer.
PURPOSE: This randomized phase III trial is studying giving gemcitabine together with or without capecitabine and/or radiation therapy to see how well it works compared with giving gemcitabine together with or without erlotinib in treating patients with locally advanced pancreatic cancer that cannot be removed by surgery. |
|
Lay Summary |
N/A |
|
WA Trial Sites |
SCGH Medical Oncology
RPH Medical Oncology |
|
Links |
Acknowledgements: US National Library of Medicine
TOPGEAR (TROG 08.08)
|
Registered Title |
A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer. |
|
Purpose |
The primary objective is to investigate whether the addition of chemoradiotherapy to chemotherapy is superior to chemotherapy alone in the neoadjuvant setting by improving pathological complete response (pCR) rates in the first instance, and subsequently overall survival, in patients undergoing adequate surgery (D1 dissection) for resectable gastric cancer. |
|
Lay Summary |
The optimal management of patients with resectable gastric cancer continues to evolve. Chemotherapy regimes are better, radiation techniques have improved and there is an increasing interest in the use of chemoradiotherapy prior to surgery for gastric cancer. The important question addressed in this trial is whether chemoradiation is better than chemotherapy alone in the treatment of resectable gastric cancer. |
|
WA Trial Sites |
Perth Radiation Oncology Centre |
|
Links |
TROG Oesophageal - TROG 03.01
|
Registered Title |
A randomised phase III study in advanced oesophageal cancer to compare quality of life and palliation of dysphagia in patients treated with radiotherapy versus chemo-therapy. |
|
Purpose |
The primary purpose of the study is to measure relief of dysphagia. This is defined as improvement of at least one point on the Mellow scale. The trial is also looking at dysphagia progression-free survival, time to achieving any response in dysphagia after treatment, number of patients receiving secondary treatment, time to achieving a complete response, quality of life, acute and late toxicities and survival. |
|
Lay Summary |
Prospective radical treatment trials in oesophageal cancer have shown responses in both radiotherapy alone and radiotherapy when combined with chemotherapy. Retrospective studies show a response in the palliative setting to relieve dysphagia. The response, durability and quality of life end points have not been previously fully documented. Carcinoma of the oesophagus has a poor prognosis with 50% of patients having Stage 4 disease at time of presentation. Dysphagia is the commonest presenting symptom due to local disease obstructing the oesophagus. Difficulty eating not only affects the patient's ability to maintain nutrition, but also impacts on all areas of quality of life. Relief of dysphagia becomes the highest priority for treatment. |
|
WA Trial Sites |
Perth Radiation Oncology Centre |
|
Links |
[Return to List of Clinical Trials]
